Early post‐operative intravenous tacrolimus in pediatric liver transplant recipients is not superior to oral tacrolimus. (4th February 2019)

• Record Type: Journal Article
• Authors: Sabra, Tarek Abdelazeem; Okajima, Hideaki; Yoshizawa, Atsushi; Ogawa, Eri; Okamoto, Shinya; Osman, Mohamed Abdelkader; Saad‐Eldin, Yasser; Uemoto, Shinji
• Is Part Of: Pediatric transplantation. Volume 23:Number 3(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-02-04
• Subjects: ACR -- pediatric liver transplantation -- TAC -- viral infection; Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.13368
• Languages: English
• ISSNs: 1397-3142

Abstract

Abstract: We aimed to compare the early results of i.v. with p.o. TAC as a primary immunosuppressant in pediatric patients undergoing LT. This retrospective study enrolled 75 children who underwent LT and received TAC‐steroid regimens as a primary immunosuppressant between September 2011 and October 2015 at our institution. Thirty‐five recipients received TAC i.v. and 40 received TAC p.o. Early results were evaluated and compared, including ACR, EBV, or CMV infection; renal adverse effects; and hospital stay. Comparisons of 90‐day post‐transplant results showed that the rates of overall viral (74% vs 40% P < 0.002), EBV (46% vs 17.5% P < 0.008), and CMV (51% vs 30% P = 0.05) infections were significantly higher in the i.v. than in the p.o. group. Neither regimen has any adverse effects on renal function. There were no between‐group differences in ACR incidence and severity, serum creatinine concentration, and hospital stay. Patient and graft survival rates at 3 months and 1 year did not differ significantly between the two groups. Compared with p.o. treatment, i.v. administration of high TAC concentration did not have beneficial post‐transplant effects on ACR incidence and severity, while increasing the incidence of viral infections in pediatric LT.